- ISIN
- US78464A7220
- CUSIP
- 78464A722
- Issuer
- State Street
- Inception Date
- Jun 19, 2006
- Region
- North America (U.S.)
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- S&P Pharmaceuticals Select Industry Index
- Distribution Policy
- Distributing
- Asset Class
- Equity
- Asset Class Size
- Multi-Cap
- Asset Class Style
- Blend
- Assets Under Management
- $503M
Highlights
- Avg. Volume (1M)
- 106K
- Avg. Volume Value (1M)
- $7.25M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
XPH Performance Chart
SPDR S&P Pharmaceuticals ETF (XPH) is up 21.8% since the beginning of the year. XPH is currently trading at $68 per share. Investors who bought $1,000 worth of XPH shares 5 years ago would now be looking at an investment worth $1,440.
Loading charts...
Compare this symbol against anything
Returns By Period
SPDR S&P Pharmaceuticals ETF (XPH) has returned 21.77% so far this year and 64.21% over the past 12 months. Over the last ten years, XPH has returned 4.97% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
SPDR S&P Pharmaceuticals ETF
- 1D
- -2.41%
- 1M
- 1.34%
- 6M
- 23.05%
- YTD
- 21.77%
- 1Y
- 64.21%
- 3Y*
- 17.71%
- 5Y*
- 7.57%
- 10Y*
- 4.97%
- ALL TIME*
- 9.38%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
XPH Monthly Returns History
Based on dividend-adjusted daily data since Jun 22, 2006, XPH's average daily return is +0.05%, while the average monthly return is +0.90%. At this rate, an investment would double in approximately 6.4 years.
Historically, 60% of months were positive and 40% were negative. The best month was Apr 2020 with a return of +16.4%, while the worst month was Sep 2015 at -18.8%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.
On a daily basis, XPH closed higher 53% of trading days. The best single day was Oct 13, 2008 with a return of +10.9%, while the worst single day was Mar 16, 2020 at -11.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.04% | 3.45% | -5.56% | 6.51% | 1.11% | 13.88% | 2.70% | 21.77% | |||||
| 2025 | 4.82% | -1.11% | -1.36% | -5.91% | -1.58% | 0.29% | 1.50% | 15.25% | 1.21% | 3.61% | 10.33% | 2.41% | 31.60% |
| 2024 | 0.91% | 5.76% | -2.51% | -7.74% | 1.61% | -1.23% | 8.67% | 3.26% | -0.19% | 3.70% | 0.41% | -6.59% | 4.94% |
| 2023 | 6.32% | -5.17% | -0.40% | 2.58% | -6.23% | 4.21% | 6.66% | -0.02% | -8.80% | -9.86% | 3.27% | 12.98% | 2.97% |
| 2022 | -5.59% | -0.62% | 4.97% | -8.77% | 1.74% | 0.37% | 2.07% | -3.08% | -3.04% | 5.38% | 1.42% | -4.14% | -9.83% |
| 2021 | -0.33% | 2.83% | -5.51% | -2.30% | 2.66% | 2.68% | -2.76% | -3.68% | -1.98% | 1.10% | -4.52% | 1.22% | -10.54% |
Benchmark Metrics
SPDR S&P Pharmaceuticals ETF has an annualized alpha of 2.92%, beta of 0.79, and R2 of 0.49 versus S&P 500 Index. Calculated based on daily prices since June 22, 2006.
- This ETF participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (91.79%) than losses (91.11%) - typical of diversified or defensive assets.
- R2 of 0.49 means the benchmark explains less than half of this ETF's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- 2.92%
- Beta
- 0.79
- R²
- 0.49
- Upside Capture
- 91.79%
- Downside Capture
- 91.11%
Expense Ratio
XPH has an expense ratio of 0.35%, placing it in the medium range.
Return for Risk
Risk / Return Rank
XPH ranks 94 for risk / return — above 94% of ETFs peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for SPDR S&P Pharmaceuticals ETF (XPH) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XPH | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.54 | ||
| Sortino ratioReturn per unit of downside risk | +1.87 | ||
| Omega ratioGain probability vs. loss probability | 1.47 | 1.25 | +0.21 |
| Calmar ratioReturn relative to maximum drawdown | 5.57 | 2.00 | +3.56 |
| Martin ratioReturn relative to average drawdown | 19.83 | 8.49 | +11.33 |
Dividends
Dividend History
SPDR S&P Pharmaceuticals ETF provided a 0.49% dividend yield over the last twelve months, with an annual payout of $0.34 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.34 | $0.46 | $0.68 | $0.53 | $0.67 | $0.44 | $0.24 | $0.29 | $0.24 | $0.29 | $0.25 | $3.66 |
Dividend yield | 0.49% | 0.83% | 1.58% | 1.28% | 1.64% | 0.95% | 0.47% | 0.64% | 0.65% | 0.67% | 0.63% | 7.15% |
Monthly Dividends
The table displays the monthly dividend distributions for SPDR S&P Pharmaceuticals ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.06 | $0.00 | $0.00 | $0.06 | $0.00 | $0.12 | |||||
| 2025 | $0.00 | $0.00 | $0.15 | $0.00 | $0.00 | $0.10 | $0.00 | $0.00 | $0.10 | $0.00 | $0.00 | $0.11 | $0.46 |
| 2024 | $0.00 | $0.00 | $0.17 | $0.00 | $0.00 | $0.16 | $0.00 | $0.00 | $0.19 | $0.00 | $0.00 | $0.15 | $0.68 |
| 2023 | $0.00 | $0.00 | $0.12 | $0.00 | $0.00 | $0.12 | $0.00 | $0.00 | $0.12 | $0.00 | $0.00 | $0.17 | $0.53 |
| 2022 | $0.00 | $0.00 | $0.18 | $0.00 | $0.00 | $0.16 | $0.00 | $0.00 | $0.13 | $0.00 | $0.00 | $0.19 | $0.67 |
| 2021 | $0.00 | $0.00 | $0.07 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.09 | $0.00 | $0.00 | $0.19 | $0.44 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the SPDR S&P Pharmaceuticals ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the SPDR S&P Pharmaceuticals ETF was 48.03%, occurring on Mar 23, 2020. Recovery took 1446 trading sessions.
The current SPDR S&P Pharmaceuticals ETF drawdown is 2.84%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-48.03%Mar 2020 | 4y 8mo | 5y 9mo | 10y 5moJul 2015 - Dec 2025 | COVID crash2020 |
-35.26%Mar 2009 | 1y 10mo | 7mo 13d | 2y 5moMay 2007 - Oct 2009 | Financial crisis2007–2009 |
-17.59%Aug 2011 | 1mo 1d | 5mo 4d | 6mo 5dJul 2011 - Jan 2012 | — |
-14.51%Apr 2014 | 1mo 9d | 2mo 7d | 3mo 16dMar 2014 - Jun 2014 | — |
-13.17%Nov 2012 | 1mo 27d | 3mo 6d | 5mo 3dSep 2012 - Feb 2013 | — |
Drawdown Indicators
| XPH | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -48.03% | -56.78% | +8.75% |
Max Drawdown (1Y)Largest decline over 1 year | -11.97% | -9.10% | -2.87% |
Max Drawdown (3Y)Largest decline over 3 years | -23.57% | -18.90% | -4.67% |
Max Drawdown (5Y)Largest decline over 5 years | -30.92% | -25.43% | -5.49% |
Max Drawdown (10Y)Largest decline over 10 years | -35.97% | -33.92% | -2.05% |
Current DrawdownCurrent decline from peak | -2.84% | -1.58% | -1.26% |
Average DrawdownAverage peak-to-trough decline | -17.13% | -10.70% | -6.43% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.35% | 2.14% | +1.21% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with XPH
Add SPDR S&P Pharmaceuticals ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with XPH